A phase I study Afatinib in Combination of Osimertinib in patients with Relapsed Non-Small Cell Lung Cancer after failure of prior Osimertinib

Not Applicable

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000031501
• Lead Sponsor: iigata Cancer Center Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-09
• Study Completion: 2022-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who are difficult to treat enrolled doses due to toxicity of afatinib 2) History of drug-induced pneumonitis, Interstitial pneumonia 3) Symptomatic brain metastasis, leptomeningitis 4) Bone metastasis to treat by operation or radiation therapy 5) Uncontrollable pleural, peritoneal or pericardial effusion 6) Prior thoracic palliative radiotherapy within 2wks 7) SCLC transformation 8) History of active double cancer 9) Severe infection 10) Active HBV infection 11) No intention to birth control 12) Unstable psychic disorder 13) Under treatment of steroid therapy or immunosuppressive therapy 14) History of allergic reaction 15) Decision of ineligibility by a physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified